Pharmafile Logo
Pharmafocus logo
Advanced Search

Sandoz

Showing 15 posts of 75 posts found.

sandoz

Novartis enters biosimilar agreement with Biocon

January 19, 2018
Medical Communications, Sales and Marketing Biocon, Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical

Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …

News
sandoz

Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data

September 15, 2017
Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical

Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …

News

FDA accepts license application for Novartis’ rituximab biosimilar

September 12, 2017
Manufacturing and Production, Sales and Marketing Novartis, Rituxan, Sandoz, biosimilar, rituximab

Sandoz, Novartis’ generics and biosimilars division, has revealed that the FDA has accepted its Biologics License Application (BLA) for a …

News
novartis_side_building

UK launch of two Novartis biosimilars could cut NHS costs

June 27, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Erelzi, Novartis, Rixathon, Sandoz, biosimilar, etanercept, rituximab

Sandoz, a division of Swiss pharma giant Novartis, has revealed that two of its biosimilars – Rixathon (biosimilar rituximab) and …

News
novartis_window

Mounting US pricing pressures cutting into quarterly sales, Novartis admits

May 31, 2017
Research and Development, Sales and Marketing Novartis, Sandoz

Novartis has revealed that increasing pressure on pricing in the US has impacted its second-quarter business, cutting into sales generated …

News
ema_building_face_web

EMA recommends suspension of 331 drugs over testing concerns

March 28, 2017
Manufacturing and Production, Sales and Marketing Aurobindo, Micro Therapeutic Research Labs, Novartis, Sandoz

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has called for the suspension of 331 drugs due to …

News
novartis_building

FDA approves Novartis Enbrel biosimilar

August 31, 2016
Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar, erzeli

Novartis, through its Sandoz division, has announced that the FDA has approved Erelzi (etanercept-szzs), a biosimilar of Amgen’s blockbuster drug …

News

FDA recommends Novartis’s biosimilar for Enbrel in unanimous vote

July 14, 2016
Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar

Sandoz, a division of Novartis, has announced that a US Food and Drug Administration (FDA) advisory committee has recommended their …

News
pfizer_enbrel

New data shows Sandoz’s Enbrel biosimilar has equivalent efficacy profile

July 7, 2016
Research and Development, Sales and Marketing Amgen, EMA, Enbrel, FDA, Novartis, Sandoz, biosimilars

Sandoz has announced new data confirming the equivalent safety and efficacy profile of their biosimilar version of Enbrel (etanercept) in …

News
novartis_side_building

Novartis aims to launch five major global biosimilars by 2020

June 21, 2016
Manufacturing and Production, Research and Development 2020, Novartis, Sandoz, biosimilars

Novartis (VTX: NOVN) has announced plans to triple its biosimilar portfolio by 2020, with the launch of five major biosimilar …

News

Sandoz biosimilars as safe and efficacious as originators, says early trials data

June 9, 2016
Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab

Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …

News
ema_building_face_web

Sandoz biosimilar accepted for regulatory submission by EMA

May 24, 2016
Manufacturing and Production, Research and Development, Sales and Marketing EMA, Sandoz, biosimilar

Sandoz, a division of Novartis, has announced that the European Medicines Agency (EMA) has accepted its marketing authorisation application for …

News

Sandoz receives EU approval for subcutaneous injection of Binocrit biosimilar

April 8, 2016
Medical Communications, Research and Development Sandoz, binocrit, biosimilar, eu approval

Sandoz has received approval from the European Commission for a type II variation for the addition of a subcutaneous route …

News
fougera

Novartis to unify Fougera’s US manufacturing plants

March 11, 2016
Manufacturing and Production, Medical Communications Fougera, Novartis, Sandoz, manufacturing

Novartis is planning to unify the two manufacturing plants used by Sandoz unit Fougera Pharmaceuticals in the US, expanding and …

News
amgen_flag

Amgen sues Novartis over Enbrel biosimilar

March 3, 2016
Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars

Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025